Evaluation of the effect of hydroalcoholic and flavonoid-enriched extracts of *Dracocephalum kotschyi* on indomethacin-induced gastric ulcer in rats

Mohsen Minaiyan1,*, Hassan Sadraei1, Iman Yousefi2, Sayed-Ebrahim Sajjadi3, and Ardeshir Talebi4

1Department of Pharmacology and Toxicology and Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
2School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
3Department of Pharmacognosy, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
4Department of Clinical Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.

Abstract

**Background and purpose:** *Dracocephalum kotschyi* (Zaringiah) is a fragrant wild medicinal plant found in Iran. Traditionally, it is used for the treatment of rheumatism, asthma, and gastrointestinal ailments. So far no investigation has been done on the beneficial or side effects of *D. kotschyi* on peptic ulcer. Therefore, this research was performed to find out whether *D. kotschyi* extract would induce peptic ulcer or could alleviate existing peptic ulcer.

**Experimental approach:** Effect of hydroalcoholic (DKHE) and flavonoid extracts (DKFE) of *D. kotschyi* were determined in normal or indomethacin-induced gastric ulcer rats (n = 6) and compared with the vehicle and ranitidine treated controls. All the treatments were carried out orally and 24 h later the stomach mucus was visually examined for peptic ulcers. A section of the stomach was taken for microscopic histopathological examinations while another section of the stomach was used for measurement of myeloperoxidase (MPO) and malondialdehyde (MDA) activities.

**Findings/Results:** Oral administration of the DKHE and DKFE alone, did not cause any sign of gastric ulcer induction. The *D. kotschyi* extracts not only didn’t aggravate the induced ulcer but also significantly prevented the severity of gastric ulcer induction by indomethacin. In addition, DKHE and DKFE inhibited MPO (up to 58.2%) and MDA (up to 44.2%) activities indicating their anti-inflammatory and antioxidant potential action on the stomach-induced ulcer.

**Conclusion and implication:** Usage of *D. kotschyi* extracts is not associated with gastric ulcer induction and its co-administration with NSAIDs would be beneficial for controlling both the inflammation and preventing gastric ulcer in diseases such as rheumatism.

**Keywords:** *Dracocephalum kotschyi*; Gastric ulcer; Indomethacin; Malondialdehyde; Pepsin; Rats.

INTRODUCTION

Peptic ulcer (gastric and duodenal) disease is a worldwide gastrointestinal (GI) disorder that arises when the caustic effects of aggressive factors like acid, pepsin, and bile dominate over the defensive factors within the GI mucosa like mucus, bicarbonate secretion, prostaglandins, blood flow, and antioxidant capacity (1). Its annual incidence is about 0.1-0.19% for outpatient and 0.03-0.17% for hospitalized diagnosed cases (2). More than 90% of gastric ulcers are happened by infection of *Helicobacter pylori* or by use of non-steroidal anti-inflammatory drugs (NSAIDs) (1).
Several medicinal plants have been studied for their potential healing effects on peptic ulcer disease among them *Glycyrrhiza glabra, Ocimum basilicum, Aloe vera, and Myrthus communis* are the most popular (3). Safety, availability, reasonable efficacy and cost are among important factors that have drawn popular attention to herbal medicines as alternative therapies for peptic ulcer disease (4). *Dracocephalum kotschyi* Boiss is the scientific name for an Iranian native plant known as Zaringiah (5). *D. kotschyi* belongs to Lamiaceae family and is a wild plant grown in cold and high-altitude mountainous areas in northern and central parts of Iran (6). Although native people living in Kouhrang region (Charamahal-Bakhtiari Province) traditionally use the boiled extract of *D. kotschyi* for the treatment of rheumatism, medicinal uses of this plant have not been well documented in validated Iranian traditional sources. Despite scarce formal information about the traditional beneficial use of *D. kotschyi*, it is used widely by indigenous people for various ailments including rheumatism, asthma, and GI disorders (4,7). In recent years a wide range of investigations has been done on the pharmacological properties of this medicinal plant. For instance, it has been suggested that its extracts have anti-hyperlipidemic (8), antidiabetic (9), anti-inflammatory, anti-allergy (10), anticancer (11), antioxidant (12), and spasmylytic activities (13). However, the most prominent pharmacological effect of *D. kotschyi* is based on its anti-inflammatory activity. For example, it has been reported that the essential oil of Zaringiah in the animal model has subsided both pain and inflammatory edema (14,15). Furthermore, an extract of *D. kotschyi* markedly inhibited both innate and adaptive immunity reactions in an animal model suggesting its immunomodulatory effect in vivo (16). In the ulcerative colitis model, pretreatment with *D. kotschyi* extract significantly prevented the induction of colitis, further emphasizing on anti-inflammatory and anti-ulcerative properties of this herbal plant (17). *D. kotschyi* is enriched with active substances that could explain why its beneficial uses have been suggested for numerous ailments. Most of the anti-inflammatory effect of *D. kotschyi* is attributed to its flavonoid’s contents including apigenin, luteolin, isokaempferide, xanthomicrol, and calycopterin (18-20). Hydroalcoholic extract of *D. kotschyi* has also potent anti-spasmodic activity on tracheal smooth muscle as well as on ileum, uterus, and bladder smooth muscles indicating its useful potential for the treatment of asthma, premature uterine contractions, and bladder inconsistency (21-23).

We know that corticosteroids have strong anti-inflammatory properties and are used for the treatment of many inflammatory and immune-based disorders. However, one of their disadvantages is that they cause and/or aggravate peptic ulcers (24). NSAIDs are also used for the treatment of rheumatism and chronic inflammatory skeletal diseases and might similarly cause peptic ulcers and/or accentuate them (25).

So far, there is no report on induction and/or aggravation of peptic ulcer due to consumption of *D. kotschyi* while several evidences suggest its potential for GI disorders such as peptic ulcer. Therefore, the current research was aimed to investigate whether oral administration of *D. kotschyi* extracts can induce gastric ulcer per se or would aggravate or alleviate existing gastric ulcer induced in the animal model.

**MATERIAL AND METHODS**

**Plant extracts preparation**

Arial parts of *D. kotschyi* were procured from a Pertian Rahnama Kesht farm in Fereydun-shahr (Isfahan province, Iran) in June 2019 and authenticated by Mohammad Asfa, a botanist from Isfahan Natural Resources Organization. A voucher specimen (No. 1519) was deposited at the herbarium of the School of Pharmacy and Pharmaceutical Sciences of Isfahan University of Medical Sciences, Isfahan, Iran. *D. kotschyi* hydroalcoholic extract (DKHE) was prepared with ethanol/water (70/30) as the solvent and by maceration method, as described before (26). The ratio of plant powder to solvent for hydroalcoholic and flavonoid enriched extracts (DKFE) were 1:10 and 1:8, respectively. The yields of hydroalcoholic and flavonoid enriched...
extracts were 28% and 40% (w/w), respectively. The total flavonoid content of DKHE and DKFE was determined by the aluminum chloride method and resulted in 0.36% and 1.12% respectively (20). DKFE was prepared from the hydroalcoholic extract by stepwise solvent/solvent partitioning technique using chloroform (2000 mL) and ethyl acetate (1/1) (27). DKHE and DKFE were prepared as 80 and 40 mg/mL stock solutions in distilled water, respectively.

**Drugs and solutions**

Indomethacin and ranitidine were prepared as 30 and 150 mg/mL stock solutions in distilled water, respectively. All the stock solutions were emulsified by adding 0.1% tween 80. Indomethacin and ranitidine were purchased from Darou-Pakhsh and Kimi-Darou Corporations (Iran), respectively.

**Gastric ulcer induction**

Gastric ulcer was induced in male Wistar rats (180-220 g) by oral administration of indomethacin using a feeding tube (28). This research project was approved by the Isfahan University of Medical Sciences Ethics Committee for the handling of laboratory animals and specified by the national ethics code: IR.MUI.Research.Rec.1398.329. Rats were purchased from the School of Pharmacy and Pharmaceutical Sciences (Isfahan University of Medical Sciences, Iran) animal house and acclimated with the laboratory environment one week before the start of the experiment. They were fasted for 24 h prior to gastric ulcer induction with free access to water. Extracts, drugs, or vehicle were given orally using a feeding tube (p.o.) to a group of 6 rats and an hour later indomethacin (30 mg/kg) was administered orally (p.o.). Altogether, eleven groups of rats were used in this study. The first group received the vehicle (distilled water/tween 80) without indomethacin. The second group was treated with the vehicle followed by administration of indomethacin. Third, fourth, and fifth groups were treated with DKHE (20, 40, 80 mg/kg) followed by indomethacin. Groups 6 to 8 were treated with DKFE (10, 20, 40 mg/kg) followed by indomethacin. The ninth group received ranitidine (30 mg/kg, i.p.) followed by indomethacin as the reference drug. Groups 10 and 11 were given vehicle followed by a single oral dose of DKHE (80 mg/kg) and DKFE (40 mg/kg), respectively instead of indomethacin to assess their possible ulcerogenic activity.

Twenty-four hour later, animals were sacrificed and the abdominal cavity was opened and both sides of the stomach were ligatured with threads before the whole stomach was dissected out.

**Measurement of pH and pepsin activity**

The stomach fluid content was collected for pH measurement and pepsin activity. Values of pH were determined by digital desktop pH meter after diluting the stomach content by 10-fold with distilled water and accounting for this dilution factor as 1 unit when pH was subsequently measured (29). Pepsin activity, on the other hand, was determined by the Anson method in gastric secretions of experimental rats.

Two mL of hemoglobin (25 g/1000 mL) was mixed with 0.5 mL of HCl (0.3 M). Then, 0.1 mL of harvested gastric acid was diluted with 9.9 mL of normal saline. Standard pepsin was used to draw the standard curve for pepsin activity while, 10 min later, 5 mL of trichloroacetic acid was added to terminate the reaction. After filtration, optical absorbance of amino acids produced by the reaction of pepsin with hemoglobin was measured at the wavelength of 280 nm, and pepsin activity was determined in terms of mg after 15 min (30).

**Macroscopic and microscopic evaluations**

The stomach was then cut into two longitudinal sections for further examination. One section was placed into formalin solution (10%) and sent for pathological examination to assess inflammation severity, hemorrhagic spot, sub-mucosal edema, and superficial mucosal ulcers (30). The other section was used for the measurement of myeloperoxidase (MPO) activity and malondialdehyde (MDA) value.

The macroscopic examination was performed on the photos taken from the stomach using Fiji P computer program (Image Analysis Program, V.2) for number and ulcer area. The microscopic examinations were scored according to Table 1.
Table 1. Pathological scores and descriptions for gastric tissue.

| Featured score       | Score | Description |
|----------------------|-------|-------------|
| Inflammation severity| 0     | None        |
|                      | 1     | Slight      |
|                      | 2     | Moderate    |
|                      | 3     | Severe      |
| Hemorrhagic spot     | 0     | None        |
|                      | 1     | Slight      |
|                      | 2     | Moderate    |
|                      | 3     | Severe      |
| Edema (sub-mucosal)  | 0     | None        |
|                      | 1     | Slight      |
|                      | 2     | Moderate    |
|                      | 3     | Severe      |
| Superficial mucosal ulcers | 0 | None |
|                      | 1     | Slight      |
|                      | 2     | Moderate    |
|                      | 3     | Severe      |

Assessment of MPO and MDA values

MPO activity was assessed by the method previously set up in our laboratory (31). MDA activity was analyzed by lipid peroxidation (MDA) assay kit (Navand-Salamat Lab Kit, Iran) according to package insert protocol was carried out previously (29,30).

Statistical analysis

All the data were expressed as mean ± standard error of the mean (SEM). Results of each group were compared with its corresponding control group. For histological results, non-parametric test (Mann-Whitney U-test) was used and the data were presented as median (range) as needed. For other data, Student's t-test and one-way ANOVA with Tukey’s post hoc test were used as appropriate.

RESULTS

Effect of DKHE and DKFE on pH values

Results of pH values suggested that indomethacin can induce acid secretion in the stomach and subsequently cause a significant decline in pH \( (P < 0.01) \) for about two units (Fig. 1). None of the treatments with herbal extracts could alter the pH significantly except for DKHE at 10 mg/kg \( (P < 0.01) \) against the control group. Ranitidine as a standard acid reducer was significantly effective to enhance pH up to 7 \( (P < 0.001) \). DKHE and DKFE alone were not effective to enhance the pH of gastric juice significantly when compared with the normal group \( (P > 0.05) \) (Fig. 1).

**Fig. 1.** pH of gastric secretions in rats. Normal rats received normal saline/tween (5 mL/kg/day), control rats with gastric ulcer induced by indomethacin (30 mg/kg). DKHE at 20, 40, and 80 mg/kg, DKFE at 10, 20, and 40 mg/kg, and ranitidine at 30 mg/kg were used. Collected data are presented as mean ± SEM, \( n = 6 \). **\( P < 0.01 \) and ***\( P < 0.001 \) show significant difference with the control group; **\( P < 0.01 \) vs the normal group. DKHE, *Dracocephalum kotschyi* hydroalcoholic extract; DKFE, *Dracocephalum kotschyi* flavonoid extract.
Antiulcerative effect of D. kotschyi

Fig. 2. Pepsin activity assessments in rat stomach. Normal rats received normal saline/tween (5mL/kg/day), control rats with gastric ulcer induced by indomethacin (30 mg/kg). DKHE at 20, 40, and 80 mg/kg, DKFE at 10, 20, and 40 mg/kg, and ranitidine at 30 mg/kg were used. Collected data are presented as mean ± SEM, n = 6. *P < 0.05, **P < 0.01, ***P < 0.001 indicate significant differences in comparison with the control group; +++P < 0.001 against the normal group. DKHE, Dracocephalum kotschyi hydroalcoholic extract; DKFE, Dracocephalum kotschyi flavonoid extract.

Effect of DKHE and DKFE on pepsin activity

Another factor was assessed in this research was pepsin activity. Pepsin activity was sharply increased (about 6 folds) in the control group that received indomethacin in comparison with the normal group (Fig. 2). Oral administration of DKHE produced no significant effect on pepsin activity however, DKFE at 10 and 20 mg/kg significantly reduced indomethacin-induced pepsin activity (Fig. 2). Oral administration of examined extracts alone caused no significant changes in pepsin activity when compared to the normal group (Fig. 2). It could be found that ranitidine fully inhibited pepsin activity induced by indomethacin and reversed it even up to the normal group value (Fig. 2).

Effect of DKHE and DKFE on macroscopic parameters

In the normal group, no sign of peptic ulcer or erosion was seen in the macroscopic parameters. In the group that received indomethacin, there was clear induction of peptic ulcer in spot or linear forms all over the stomach lining (Fig. 3). Both DKHE and DKFE reduced the severity and extent of indomethacin-induced ulcer (Fig. 3). DKHE and DKFE significantly reduced indomethacin-induced ulcer numbers when lower doses of extracts were applied (Fig. 4).
Comparison of ulcer area showed that in the animal group treated with DKHE (20, 40, and 80 mg/kg) the ulcer area was reduced 62, 55, and 29%, respectively. In a similar way, DKFE (10, 20, and 40 mg/kg) reduced indomethacin-induced ulcer area by 75, 48, and 35%, respectively (Fig. 5). Ranitidine reduced both ulcer number (61%) and ulcer area (91%) induced by indomethacin in a meaningful manner (Figs. 4 and 5).

**Fig. 4.** Numerical assessment of ulcers in rat’s stomach. Normal rats received normal saline/tween (5 mL/kg/day), control rats with gastric ulcer induced by indomethacin (30 mg/kg). DKHE at 20, 40, and 80 mg/kg, DKFE at 10, 20, and 40 mg/kg, and ranitidine at 30 mg/kg were used. Collected data are presented as mean ± SEM, n = 6. **P < 0.01 and ***P < 0.001 show significant differences in comparison with the control group; +++P < 0.001 in contrast with the normal group. DKHE, *Dracocephalum kotschyi* hydroalcoholic extract; DKFE, *Dracocephalum kotschyi* flavonoid extract.

**Fig. 5.** Assessment of ulcer area in rat’s stomach. Normal rats received normal saline/tween (5 mL/kg/day), control rats with gastric ulcer induced by indomethacin (30 mg/kg). DKHE at 20, 40, and 80 mg/kg, DKFE at 10, 20, and 40 mg/kg, and ranitidine at 30 mg/kg were used. Collected data are presented as mean ± SEM, n = 6. **P < 0.01 and ***P < 0.001 show significant differences with the control group; +++P < 0.001 vs the normal group. DKHE, *Dracocephalum kotschyi* hydroalcoholic extract; DKFE, *Dracocephalum kotschyi* flavonoid extract.
Table 2. Microscopic features of rat stomach tissue in different groups. Normal rats received normal saline/tween (5 mL/kg); control, the gastric ulcer was induced by indomethacin (30 mg/kg). DKHE, DKFE, and ranitidine (30 mg/kg) were given orally prior to indomethacin.

| Groups/dose (mg/kg) | Ulcer severity Median (range) (0-12) |
|---------------------|-------------------------------------|
| Normal rats         | 0 (0-0)                             |
| Control             | 11 (8-12) +++                      |
| DKHE 20 + indomethacin 30 | 4 (4-8) ***                    |
| DKHE 40 + indomethacin 30 | 8 (2-8) **                      |
| DKHE 80 + indomethacin 30 | 10 (4-12) **                      |
| DKFE 10 + indomethacin 30 | 4 (3-9) ***                      |
| DKFE 20 + indomethacin 30 | 8 (3-10) **                      |
| DKFE 40 + indomethacin 30 | 10 (4-12)                      |
| Ranitidine 30       | 3 (2-6) ***                         |
| DKHE 40             | 0 (0-0)                             |
| DKFE 80             | 0 (0-0)                             |

DKHE, *Dracocephalum kotschyi* hydroalcoholic extract; DKFE, *Dracocephalum kotschyi* flavonoid extract. **P < 0.01 and ***P < 0.001 show statistically significant difference compared with the control group; ***P < 0.001 significant difference vs normal group, (n = 6). Two later groups (DKHE and DKFE) were compared with the normal group.

Effect of DKHE and DKFE on microscopic parameters

As it is shown in Table 2, tissue samples were unaffected in the normal group. In the control group that received indomethacin orally and treated with vehicle, inflammation severity, hemorrhagic spot, sub-mucosal edema, superficial mucosal ulcers were found as the most severe changes in gastric tissue (Table 2).

All doses of DKHE and DKFE fractions reduced microscopic features significantly (at least P < 0.01) compared to the control group, although in groups that received DKHE 80 mg/kg and DKFE 40 mg/kg improving pathological parameters were not significant (Table 2, Fig. 6). In the reference group that received ranitidine, these pathological features were improved significantly compared to the control group (Table 2, Fig. 6). On the other side, DKHE (80 mg/kg) and DKFE (40 mg/kg) alone couldn’t produce any sign of ulcer or erosion in gastric mucosa indicating its safety as complementary herbal medicine (Table 2, Fig. 6).

Fig. 6. Microscopic evaluation of gastric tissue injuries induced by indomethacin in rats. (A) Normal tissue treated with normal saline/tween, (B) control group that received indomethacin (30 mg/kg), (C) gastric ulcer treated with *Dracocephalum kotschyi* hydroalcoholic extract (20 mg/kg), (D) gastric ulcer treated with *Dracocephalum kotschyi* flavonoid extract (10 mg/kg), and (E) gastric ulcer treated with ranitidine (30 mg/kg). Black arrows show improvement and healing of ulcers in the extract-treated groups versus the control.
**Effects of DKHE and DKFE on MPO activity**

Measurement of MPO activity has been used as an indication of tissue inflammation. In the normal group, treated with vehicle, only a residual MPO activity was observed, while in the indomethacin-treated control group MPO activity has substantially been elevated (Fig. 7). Administration of DKHE and DKFE produced variable changes in MPO activity in comparison with the control group albeit two lower doses of DKHE (20 and 40 mg/kg; \( P < 0.05 \)) and the middle dose of DKFE (20 mg/kg) were practically effective (\( P < 0.01 \)) in this regard. Ranitidine also inhibited MPO activity significantly (\( P < 0.01 \)) (Fig. 7). DKHE and DKFE did not present a different picture of MPO activity versus the normal group when applied alone (\( P > 0.05 \)) (Fig. 7).

**Effect of DKHE and DKFE on MDA value**

MDA indicates lipid oxidation and acts as another marker for tissue inflammation and oxidative stress. As it is shown in Fig. 8, only a basal level of lipid oxidation was seen in the normal tissues. Animals treated with oral indomethacin represented a great increase in MDA level over the treatment course. Pretreatment of animals with DKHE (20 mg/kg) and DKFE (10 mg/kg) significantly inhibited lipid oxidation induced by indomethacin (Fig. 8). By increasing oral doses of the extracts, the antioxidant activity of the extracts was unexpectedly diminished. Ranitidine reduced lipid oxidation activity induced by indomethacin significantly (\( P < 0.001 \)) (Fig. 8). DKHE and DKFE alone didn’t alter MDA value in comparison to normal tissue (\( P > 0.05 \)) (Fig. 8).

![Graph showing MPO activity assessments in rat’s stomach](image_url)

**Fig. 7.** MPO activity assessments in rat’s stomach. Normal rats received normal saline/tween (5 mL/kg/day), control rats with gastric ulcer induced by indomethacin (30 mg/kg), DKHE at 20, 40, and 80 mg/kg, DKFE at 10, 20, and 40 mg/kg, and ranitidine at 30 mg/kg were used. Collected data are presented as mean ± SEM, \( n = 6 \). *\( P < 0.05 \) and **\( P < 0.01 \) show significant differences compared with the control group and ***\( P < 0.001 \) against the normal group. DKHE, *Dracocephalum kotschyi* hydroalcoholic extract; DKFE, *Dracocephalum kotschyi* flavonoid extract; MPO, myeloperoxidase.
Antiulcerative effect of D. kotschyi

Fig. 8. MDA level assessment in rat’s stomach. Normal rats received normal saline/tween (5 mL/kg/day), control rats with gastric ulcer induced by indomethacin (30mg/kg). DKHE at 20, 40, and 80 mg/kg, DKFE at 10, 20, and 40 mg/kg, and ranitidine at 30 mg/kg were used. Collected data are presented as mean ± SEM, n = 6. *P < 0.05, **P < 0.01, and ***P < 0.001 show significant difference with the control group; +++P < 0.001 against the normal group. DKHE, Dracocephalum kotschyi hydroalcoholic extract; DKFE, Dracocephalum kotschyi flavonoid extract; MDA, malondialdehyde.

DISCUSSION

Peptic ulcer is a common problem of anti-inflammatory drugs such as NSAIDs and corticosteroids (1). The underlying cause of peptic ulcer induction by these drugs is based on their ability to inhibit prostaglandin production (32). Indomethacin is a potent inhibitor of cyclooxygenase enzymes which is responsible for the synthesis of prostaglandins and thereby reduces prostaglandin necessary for the maintenance of stomach protective layers (33,34). D. kotschyi possessed anti-inflammatory activities and its anti-inflammatory action has been likely attributed to its flavonoid’s contents (4,17). It has been suggested that some flavonoids inhibit prostaglandin production (35). D. kotschyi is enriched in flavonoids but so far there is no report about the net effect of D. kotschyi extract on the stomach ulcer. Therefore, the objective of this research was to find out if, similar to chemical anti-inflammatory agents, D. kotschyi extract has the potential to cause peptic ulcer or inversely its consumption might be beneficial for patients with a history of peptic ulcer alike many flavonoids-enriched herbals (4).

Therefore, a validated animal model of induced peptic ulcer by indomethacin was currently used in order to address these questions (28). As expected, indomethacin produced evident damages to the lining of the stomach wall. However, D. kotschyi extracts alone at doses with anti-inflammatory and anti-spasmodic activity, did not cause any kind of stomach ulcer. On the other hand, DKHE and DKFE extracts prevented stomach ulcer induced by indomethacin indicating that they might exert a sort of protective function against peptic ulcer. By considering pepsin activity and pH of gastric secretions, it was found out that pepsin was likely more affected by herbal extracts however, pH was not changed significantly. This might present a piece of evidence that the protective effect of herbal extracts was mediated through a direct reaction of extract ingredients with pepsin molecules rather than hydrochloric acid suppression. This protection was inversely dependent on the dose and with increasing the dose, it tends to be reversed as previously shown by other experiments (17). This may indicate that there are some constituents within the extracts that either antagonize the ulcer...
healing effect or potentiating nonspecific anti-inflammatory action of extract at larger doses on the GI tract (36).

More interestingly, a similar pattern of anti-inflammatory and anti-ulcerative action has been seen on the colitis-induced ulcer with *D. kotschyi* extract (17). Measurement of MPO activity is widely used for the assessment of gastrointestinal inflammation (31,37). Oral administration of *D. kotschyi* extracts reduced enzymatic activity of MPO, however, the effect was not fully consistent with the hypothesis that flavonoids are the main ingredients for this purpose. Therefore, it can be concluded that the reduction in peptic ulcer extent and severity observed by *D. kotschyi* extracts administration partially might be due to its anti-inflammatory property and some other constituents like alkaloids, essential oils, tannins, etc. (7,12,20). MDA is a highly reactive natural compound that is associated with lipid peroxidation which is an indicator of tissue injury (38). Reduction in MDA levels by *D. kotschyi* extracts indicates a reduction in tissue oxidative stress. Increased levels of MDA have been reported in patients with rheumatism (39). Therefore, it seems that the anti-ulcer properties of *D. kotschyi* extracts could be at least, in some part, due to antioxidant ingredients within the extract. Antioxidant activity is generally attributed to phenolic compounds which flavonoids and flavonols are among the most characterized in extracts. Since the lowest doses of extracts exhibited the greatest decline in MDA activity, therefore it seems that extracts also contain peroxidant constituents tend to limit this capacity for healing effects of extracts. In this research, flavonoids fraction was also studied because they have been reported as potential anti-inflammatory reagents (21). Flavonoids such as apigenin, luteolin, acatein, and their glucopyranoside derivatives, calycocpterin, xanthomicrol, isokaempferide, and limonene are among the most abundant and important flavonoids are present in extracts (7). The anti-inflammatory effect of flavonoids is suggested to be due to inhibition of pro-inflammatory cytokine-induced chemokine expression (40). Apigenin is one of the flavonoids constituents identified in the hydroalcoholic extract of *D. kotschyi* (36). The anti-ulcerative effect of apigenin has already been reported in an animal model of colitis (17). The anti-inflammatory effect of apigenin is reported to be due to inhibition of nitric oxide synthase and cyclooxygenase-2 enzymes induction (41). Inhibition of interleukin-4 production and suppression of tumor necrosis factor-α elevations might also be involved (42). Luteolin is another flavonoid constituent found in *D. kotschyi* extract with similar structures and anti-inflammatory properties to apigenin (22).

CONCLUSION

Unlike corticosteroid and NSAIDs, oral administration of *D. kotschyi* extracts neither caused peptic ulcer nor aggravated indomethacin-induced peptic ulcer. In fact, *D. kotschyi* extracts had a protective effect against indomethacin-induced ulcer. So, it can be suggested that consumption of *D. kotschyi* extracts preparation would be likely safe in patients with a history of peptic ulcer. However, there is a long way to introduce this medicinal plant for clinical application, and more detailed mechanistic, clinical trial, and toxicological studies are warranted for this purpose.

Acknowledgements

This study was financially supported by the Vice-Chancellor for Research and Technology in Isfahan University of Medical Sciences under Grant No. 398383.

Conflict of interest statement

The authors declared no conflict of interest in this study.
Authors’ contribution

H. Sadraei drafted the primary manuscript and contributed to data analysis and depicting the graphs and tables. I. Yousefi drafted the proposal and carried out all the experimental procedures as well as analysis of the data and representing the results. S.E. Sajjadi introduced the candidate plant while supervised the preparation of extracts and their standardization. A. Talebi prepared suitable tissue samples for pathological studies and their interpretation. M. Minaiyan represented the idea, drafted the final modified manuscript and supervised all the steps of procedures, data analysis and their interpretation.

REFERENCES

1. McQuaid KR. Drugs Used in the Treatment of Gastrointestinal Diseases. 14th ed. New York: McGraw Hill; 2018: pp: 1087-1094.

2. Sung JJY, Kuipers EJ, El‐Kotschyi and polyphenolic fraction from Antihyperlipidemic effect of hydroalcoholic extract, DOI: 10.1016/s0031-6865(98)00016-8.

3. Wei-Ping B, Hui-Bin M, Mao-Qiang M. Efficacy and safety of herbal medicines in treating gastric ulcer: a review. World J Gastroenterol. 2014;20(45):17020-17028. DOI: 10.3748/wjg.v20.i45.17020.

4. Kuna L, Jakab J, Smolic R, Raguz-Lucic N, Vcev A, Smolic M. Peptic ulcer disease: a brief review of conventional therapy and herbal treatment options. J Clin Med. 2019;8(2):179-197. DOI: 10.3390/jcm80200179.

5. Naghibi F, Mosaddegh M, Mohammadi-Motamed M, Ghorbani A. Labiatae family in folk medicine in Iran: from ethnomedicine to pharmacology. Iran J Pharm Res. 2010;4(2):63-79.

6. Sonboli A. Molecular characterization of Iranian Dracocephalum (Lamiaceae) species based on RAPD data material and methods plant material DNA extraction screening and PCR amplification with RAPD primers. Acta Biol Szegediensis. 2011;55(2):227-230.

7. Heydari P, Yavari M, Adibi P, Asghari G, Ghanadian SM, Dida GO, et al. Medicinal properties and active constituents of Dracocephalum kotschyi and its significance in Iran: a systematic review. Evid Based Complement Alternat Med. 2019;2019:9465309, 1-14. DOI: 10.1155/2019/9465309.

8. Sajjadi SE, Movahedian Atar AM, Yektaia A. Antihyperlipidemic effect of hydroalcoholic extract, and polyphenolic fraction from Dracocephalum kotschyi Boiss. Pharm Acta Helv. 1998;73(3):167-170. DOI: 10.1016/s0031-6865(98)00016-8.

9. Eskandari M, Mohammadi J, Delaviz H, Hossieni E. The effects of hydroalcoholic extract of Dracocephalum kotschyi on blood glucose and lipid profile in diabetic rats. J Fasa Univ Med Sci. 2016;5(4):526-533.

10. Kalantar K, Gholijani N, Mousaei N, Yazdani M, Amirghofran Z. Investigation of Dracocephalum kotschyi plant extract on the effective inflammatory transcription factors and mediators in activated macrophages. Antinflamm Antiallergy Agents Med Chem. 2018;17(1):39-49. DOI: 10.2174/1871523017666180608081656.

11. Jahaniyan F, Ebrahimi SA, Rahbar-Roshandel N, Mahmoudian M. Xanthomucol is the main cytotoxic component of Dracocephalum kotschyi and a potential anti-cancer agent. Phytochemistry. 2005;66(13):1581-1592. DOI: 10.1016/j.phytochem.2005.04.035.

12. Ashrafi B, Kamak P, Ezatpour B, Talei GR. Investigation on chemical composition, antimicrobial, antioxidant, and cytotoxic properties of essential oil from Dracocephalum kotschyi Boiss. Afr J Tradit Complement Altern Med. 2017;14(3):209-217. DOI: 10.21010/ajtcam.v14i3.23.

13. Ghavam M, Manconi M, Manco ML, Bachetta G. Extraction of essential oil from Dracocephalum kotschyi Boiss. (Lamiaceae), identification of two active compounds and evaluation of the antimicrobial properties. J Ethnopharmacol. 2021;267:1-26. DOI.org/10.1016/j.jep.2020.113513.

14. Sadraei H, Asghari G, Kasiri F. Comparison of antispasmodic effects of Dracocephalum kotschyi essential oil, limonene and alpha-terpineol. Res Pharm Sci. 2015;10(2):109-116.

15. Golshani S, Karamkhani F, Monsef-Esfehani HR, Abdollahi M. Antinociceptive effects of the essential oil of Dracocephalum kotschyi in the mouse writhing test. J Pharm Pharm Sci. 2004;7(1):76-79.

16. Faham N, Javidnia K, Bahmani M, Amirghofran Z. Calycopererin, an immunoinhibitory compound from the extract of Dracocephalum kotschyi. Phytother Res. 2008;22(9):1154-1158. DOI: 10.1002/ptr.2382.

17. Sadraei H, Asghari G, Khanabadi M, Minaiyan M. Anti-inflammatory effect of apigenin and hydroalcoholic extract of Dracocephalum kotschyi on acetic acid-induced colitis in rats. Res Pharm Sci. 2017;12(4):322-329. DOI: 10.4103/1735-5362.212050.

18. Serafini M, Peluso I, RaguzziniA. Flavonoids as anti-inflammatory agents. Proc Nutr Soc. 2010;69(3):273-278. DOI: 10.1017/S002966551000162X.

19. Kamali M, Khozroy S, Kamali H, Ahmadzade Sani T, Mohammadi A. Phytochemical screening and evaluation of antioxidant activities of Dracocephalum kotschyi and determination of its luteolin content. Avicenna J Phytomed 2016;6(4):425-433. DOI: 10.22038/ajp.2016.6377.
20. Sadraei H, Ghanadian SM, Moazeni S. Inhibitory effect of hydroalcoholic and flavonoids extracts of *Dracocephalum kotschyi*, and its components luteolin, apigenin and apigenin-4′-galactoside on intestinal transit in mice. J Herbmed Pharmacol. 2019;8(1):8-13. DOI: 10.15171/jhp.2019.02.

21. Sadraei H, Ghanadian SM, Asghari G, Gavahian A. Bronchodilator effect of apigenin and luteolin, two components of *Dracocephalum kotschyi* on isolated rabbit trachea. J Herbmed Pharmacol. 2019;8(4):281-286. DOI: 10.15171/jhp.2019.41.

22. Choi JR, Lee CM, Jung ID, Lee JS, Jeong YI, Chang JH, et al. Apigenin protects ovalbumin-induced asthma through the regulation of GATA-3 gene. Int Immunopharmacol. 2009;9(7-8):918-924. DOI: 10.1016/j.intimp.2009.03.018.

23. Sadraei H, Ghanadian M, Asghari G, Sekhavati N. Antispasmodic activity of apigenin and luteolin, two components of *Dracocephalum kotschyi* extract, on rat ileum contractions. J Herbmed Pharmacol. 2018;7(2):100-105. DOI: 10.15171/jhp.2018.17.

24. Buttgerit F, Saag KG, Cutofo M, da Silva JA, Bijlsma JW. The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand J Rheumatol. 2005;34(1):14-21. DOI: 10.1080/03009740510017706.

25. Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and its components. J Herbmed Pharmacol. 2019;8(4):281-35.

26. Handa SS, Khanuja SP, Lango G, Rakesh DU. Extraction Technologies for Medicinal and Aromatic Plants. Italy, Trieste: Earth, Environmental and Marine Sciences and Technologies International Centre for Science and High Technology; 2008. pp: 869.

27. Ghasemi Dehkordi NA, Sajadi SE, Ghanadi AR, Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith. DOI: 10.15171/jhp.2018.17.

28. Grotto D, Maria LS, Valentini J, Paniz C, Schmitt G, Garcia SC, et al. Importance of the lipid peroxidation biomarkers and methodological aspects for malondialdehyde quantification. Quimica Nova. 2009;32(1):63-69.

29. Grotto D, Maria LS, Valentini J, Paniz C, Schmitt G, Garcia SC, et al. Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin Biochem. 2005;38(10):951-955. DOI: 10.1016/j.clinbiochem.2005.06.010.

30. Grotto D, Maria LS, Valentini J, Paniz C, Schmitt G, Garcia SC, et al. Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin Biochem. 2005;38(10):951-955. DOI: 10.1016/j.clinbiochem.2005.06.010.